Key result
Substituted phenyl analogues of 5-[[4-(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles showed enhanced in vitro activity against human rhinovirus, with mean MICs as low as 0.40 microM.
Population
Human rhinovirus (HRV) serotypes (in vitro model)
Comparison
Substituted phenyl analogues of… vs Unsubstituted compound
Design
Preclinical
Authors
Loading...
Warrants preclinical testing of these analogues; leaves open whether in vitro potency translates to clinical rhinovirus treatment.
Substituted phenyl analogues of 5-[[4-(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles show potent in vitro inhibitory activity against human rhinovirus serotypes.
Diana et al. (1987) studied Human rhinovirus (HRV). Substituted phenyl analogues of 5-[[4-(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles vs. Unsubstituted compound was evaluated on Mean MIC against five HRV serotypes. Substituted phenyl analogues of 5-[[4-(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles showed enhanced in vitro activity against human rhinovirus, with mean MICs as low as 0.40 microM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: